Physician
Di Toro, Linda
Di Toro, Linda was paid $1.22M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 60% of everything it billed.
33Billing provider infoDI TORO, LINDA
STATEN ISLAND, NY 10309
STATEN ISLAND, NY 10309
33aNPI1245205798assigned 02/20/2006
33bProvider typePediatrics Physician
28Total paid$1.22M
24GClaims37,932
24DCodes billed35
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in New York
Rank by total paid#250 of 1,983
Median peer was paid$17K
This provider vs. median72×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,199 | $132K | |
| 2019 | 5,521 | $180K | |
| 2020 | 5,642 | $146K | |
| 2021 | 5,592 | $180K | |
| 2022 | 6,799 | $226K | |
| 2023 | 5,431 | $192K | |
| 2024incomplete | 4,748 | $169K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 60% | 11,615 | 9,131 | $736K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.4% | 1,021 | 974 | $91K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.9% | 1,151 | 1,116 | $84K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 5.3% | 3,911 | 3,784 | $65K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.2% | 787 | 782 | $64K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.8% | 575 | 574 | $46K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.2% | 2,439 | 1,186 | $27K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.1% | 336 | 334 | $26K |
| 99401 | 1.7% | 1,294 | 1,239 | $21K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 3,758 | 3,456 | $19K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 492 | 468 | $18K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,896 | 2,816 | $12K |
23 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,091 | $5K |
| 86328 | <1% | 96 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 93 | $4K |
| 99050 | <1% | 193 | $1K | |
| 92588 | <1% | 12 | $667.92 | |
| 90461 | <1% | 137 | $198.52 | |
| 83655 | <1% | 13 | $133.77 | |
| 36416 | <1% | 2,668 | $66.72 | |
| 99000 | <1% | 299 | $55.11 | |
| 81002 | <1% | 31 | $53.51 | |
| 90688 | <1% | 64 | $0.07 | |
| 90686 | <1% | 516 | $0.05 | |
| 90716 | 0% | 25 | $0.00 | |
| 90619 | 0% | 29 | $0.00 | |
| 99070 | 0% | 14 | $0.00 | |
| 90656 | 0% | 13 | $0.00 | |
| 90713 | 0% | 122 | $0.00 | |
| 90670 | 0% | 139 | $0.00 | |
| 90648 | 0% | 70 | $0.00 | |
| 99072 | 0% | 769 | $0.00 | |
| 90700 | 0% | 234 | $0.00 | |
| 90685 | 0% | 14 | $0.00 | |
| 90734 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.